



The 4<sup>th</sup> World Congress on

## CONTROVERSIES TO CONSENSUS IN DIABETES, OBESITY AND HYPERTENSION (CODHy)

BARCELONA, SPAIN • NOVEMBER 8-11, 2012

Preliminary Scientific Program

	Thursday	Friday	Saturday	Sunday
	Hall A			
<b>Plenary Session 1</b>	<b>08:30-10:00</b>	<b>Diabetes and Cancer</b> <b>Chairs: S. Del Prato, Italy and I. Raz, Israel</b> Pathogenesis of cancers in diabetes and obesity <b>D. Leroith, USA</b> Insulin therapy and cancer <b>P. Home, UK</b> Oral agents and cancer (metformin, sulfonylureas, thiazolidinediones) <b>R.A. DeFronzo, USA</b> Newer therapies and cancer (incretin and SGLT2) <b>M. Nauck, Germany</b> Discussion: Do we need malignancy outcome studies?		
	<b>10:00-10:30</b>	<i>Coffee Break</i>		
<b>Session 2</b>	<b>10:30-12:00</b>	<b>Controversies in Diabetes Treatment</b> <b>Chairs: P. Djordjevic, Serbia &amp; B. Gallwitz, Germany</b> How to start pharmacologic treatment? Patho-physiological driven approach vs. guideline approach Patho-physiological driven approach: <b>R.A. DeFronzo, USA</b> Guideline approach: <b>I. Raz, Israel</b> How do we continue treatment of secondary failure? Incretin vs. insulin treatment Incretin: <b>B. Gallwitz, USA</b> Insulin: <b>R.G. Bretzel, Germany</b>		
	<b>12:00-13:30</b>	<i>Lunch Break</i>		
<b>Session 3</b>	<b>13:30-15:30</b>	<b>Diabetes, Obesity and Hypertension</b> <b>Chair: A. Lejnieks, Latvia</b> Should we be targeting subclinical organ damage? Yes: <b>E. Grossman, Israel</b> No: <b>G. Mancia, Italy</b> Should our targets for control be different in the elderly? Obesity <b>C. Tsigos, Greece</b> Blood pressure control <b>G. Grassi, Italy</b> Lipid control <b>R. Bitzur, Israel</b> Blood glucose control <b>Y. Kleinman, Israel</b>		
	<b>15:30-16:00</b>	<i>Coffee Break</i>		
<b>Session 4</b>	<b>16:00-17:30</b>	<b>Diabetes and Related Disorders</b> <b>Chair: P. Home, UK</b> Sleep disorders <b>S. Sadikot, India</b> Pancreatitis <b>G. Marchesini, Italy</b> Diabetes, Dysglycemia and cognitive dysfunction		

T. Cukierman-Yaffee. Israel

Hall B		
<b>Session 5</b>	<b>10:30-12:00</b>	<p><b>News in Hypertension</b>  <b>Chair: L. Ruilope, Spain</b></p> <p>Individualization of the management of hypertension  <b>G. Mancia, Italy</b></p> <p>Blood pressure (BP) variability or average BP is the main determinant of future cardiovascular (CV) outcomes  Pro BP-variability: <b>G. Parati, Italy</b>  Pro-average BP: <b>L. Ruilope, Spain</b></p> <p>Diagnosis of hypertension should be by ambulatory monitoring  Pro: <b>E. Grossman, Israel</b>  Con: <b>P. Nilsson, Sweden</b></p>
12:00-13:30 <i>Lunch Break</i>		
<b>Session 6</b>	<b>13:30-15:30</b>	<p><b>Obesity and Weight Loss</b>  <b>Chair: D. Micic, Serbia</b></p> <p>Is obesity a brain disease?  Yes: <b>N. Stern, Israel</b>  No: <b>N. Finer, UK</b></p> <p>Cardiovascular risk factor: The obesity paradox - Does it exist?  Against: <b>E. Standl, Germany</b>  In favor: <b>V. Hainer, Czech Republic</b></p> <p>Physical exercise is a core element for every patient  Yes: <b>P.P. De Feo, Italy</b>  No: <b>P. Schwarz, Denmark</b></p>
15:30-16:00 <i>Coffee Break</i>		
<b>Session 7</b>	<b>16:00-17:30</b>	<p><b>Bariatric Surgery</b>  <b>Chair: L. Sjostrom, Sweden</b></p> <p>Mechanism of metabolic advantage after bariatric surgery  It's all food restrictions: <b>R. Taylor, UK</b>  It's all gastro-intestinal factors: <b>F.K. Knop, Denmark</b></p> <p>Can surgery during adolescence be justified?  Yes: <b>R. Weiss, Israel</b>  No: <b>J.C. Holm, Denmark</b></p>
Hall C		
<b>Session 8</b>	<b>10:30-12:00</b>	<p><b>Unmet Needs in Obesity</b>  <b>Chairs: L. Van Gaal, Belgium &amp; R. Weiss, Israel</b></p> <p>Obesity treatments: The state of the art  <b>L. Van Gaal, Belgium</b></p> <p>Bariatric surgery in the prevention of type 2 diabetes: Long term experiences from the SOS study  <b>L. Sjostrom, Sweden</b></p> <p>From bariatric surgery to bariatric pill  <b>G. Lieberman, Israel</b></p> <p>Combining surgery and pharmacologic treatment  <b>D. Dicker, Israel</b></p>
12:30-13:30 <i>Lunch Break</i>		
<b>Session 9</b>	<b>13:30-15:30</b>	<p><b>The Kidney As a New Therapeutic Partner</b>  <b>Chair: G. Scherthaner, Austria</b></p> <p><i>Supported by Janssen, Pharmaceutical Companies of Johnson &amp; Johnson</i></p> <p>Hyperglycaemia, hypertension, obesity, and the kidney in people with T2D  <b>L. Van Gaal, Belgium</b></p> <p>The kidney as a new therapeutic partner  <b>J. Wilding, UK</b></p> <p>Clinical potential of SGLT-2 inhibition  <b>J. Seufert, Germany</b></p> <p>How this new approach may help tackle clinical inertia  <b>M. Puig Domingo, Spain</b></p>
15:30-16:00 <i>Coffee Break</i>		
<b>Session 10</b>	<b>16:00-17:30</b>	<p><b>Ongoing Discussions in Diabetes and Metabolic Syndrome</b>  <b>Chair: J. Skrha, Czech Republic</b></p> <p>Postprandial hyperglycaemic variability: Should we care?  Yes: <b>A. Ceriello, Spain</b></p>

No: **E.S. Kilpatrick**, UK

NAFLD/NASH- Is it an independent predictor of CV disease?

**E. Bonora**, Italy

**18:00-20:30** Bristol-Meyers Squibb / AstraZeneca Satellite Symposium



[info@comtecmed.com](mailto:info@comtecmed.com)  
[www.comtecmed.com](http://www.comtecmed.com)

**Headquarters & Administration:**

53 Rothschild Boulevard,  
PO Box 68,  
Tel Aviv, 61000, Israel  
Tel: +972-3-5666166  
Fax: +972-3-5666177  
Email: [Info@comtecmed.com](mailto:Info@comtecmed.com)

**Comtec Spain:**

Bailen, 95 - 97,  
pral.1.a - 08009  
Barcelona, Spain  
Tel: +34-932081145  
Fax: +34-934579291  
Email: [spain@comtecmed.com](mailto:spain@comtecmed.com)

**Comtec China:**

Suite 405, Universal Center Building  
175 Xiang Yang Road South,  
Shanghai 200031, China  
Tel: +86-21-54660460  
Fax: +86-21-54660450  
Email: [china@comtecmed.com](mailto:china@comtecmed.com)